Myelofibrosis Secondary to PV and ET Prognostic Model
Loading...
years
References
- Matteo Guerra. Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC‐PM. American Journal of Hematology, 2024
- K. Shide. Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model. Blood Cancer Journal, 2023
- D. Luque Paz. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.. Blood advances, 2021
- J. How. A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic.. Journal of the National Comprehensive Cancer Network : JNCCN, 2020
- F. Passamonti. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia, 2017
- Tiziano Barbui. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011
- C. Tam. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009